DSGN logo

DSGN
Design Therapeutics Inc

436
Mkt Cap
$693.27M
Volume
863,636.00
52W High
$17.25
52W Low
$3.33
PE Ratio
-9.30
DSGN Fundamentals
Price
$11.13
Prev Close
$11.10
Open
$10.96
50D MA
$12.31
Beta
1.64
Avg. Volume
498,579.69
EPS (Annual)
-$1.22
P/B
3.18
Rev/Employee
$0.00
$319.45
Loading...
Loading...
News
all
press releases
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.read more...
Benzinga·3d ago
News Placeholder
More News
News Placeholder
Nasdaq Down 200 Points; Brady Earnings Top Views
US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs...
Benzinga·3d ago
News Placeholder
Jim Cramer on Design Therapeutics: Pure Spec, Pure Spec
Jim Cramer on Design Therapeutics: Pure Spec, Pure Spec...
Yahoo! Finance: News·4d ago
News Placeholder
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock
Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares declined 0.8% to close at $95.43.read more...
Benzinga·6d ago
News Placeholder
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·10d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Design Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·20d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5% - Should You Sell?
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5% - What's Next...
MarketBeat·21d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High Following Earnings Beat
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year High Following Earnings Beat...
MarketBeat·22d ago
News Placeholder
Design Therapeutics Q1 Earnings Call Highlights
Design Therapeutics (NASDAQ:DSGN) outlined its strategy and trial design for DT-216 in Friedreich's ataxia (FA), emphasizing that its ongoing RESTORE-FA multiple ascending dose study is intended to determine whether the therapy can meaningfully increase endogenous frataxin levels and help define a p...
MarketBeat·22d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Posts Earnings Results, Beats Expectations By $0.07 EPS
Design Therapeutics (NASDAQ:DSGN - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.36) by...
MarketBeat·23d ago
<
1
2
...
>

Latest DSGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.